InvestorsHub Logo
icon url

kgromax

08/20/21 8:58 AM

#179909 RE: misiu143 #179907

Nope it is for severe patients (using the common definition found in most studies in the litterature), which is not nothing. This is precisely the vast majority of patients reaching hospitals (criticals being a minority). This potential treatment is spot on.
icon url

misiu143

08/20/21 9:26 AM

#179916 RE: misiu143 #179907

I think this Israeli drug also work with CD24 , as Oncoimmune drug Merck bought ,

I know that Merck just gave up with this development.

I don't have a time to do deeper DD now , but I think I am right..

All IMO.
icon url

stockorus

08/20/21 9:41 AM

#179922 RE: misiu143 #179907

I mentioned in post 179516 that our “moderately ill” in Brazil includes a large subgroup of those considered Critical in cd12. Only ECMO level patients fall in Critical category in Brazil.

If that is correct, then yes from the standpoint of LL, the distinctions we presently have for these categories apply at a later stage of the disease, and it will not be appropriate to conflate our “moderately ill” with what others consider severe.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165495852